Improvement of Left Ventricular Graft Function Using an Iron-Chelator-Supplemented Bretschneider Solution in a Canine Model of Orthotopic Heart Transplantation

Demand for organs is increasing while the number of donors remains constant. Nevertheless, not all organs are utilized due to the limited time window for heart transplantation (HTX). Therefore, we aimed to evaluate whether an iron-chelator-supplemented Bretschneider solution could protect the graft in a clinically relevant canine model of HTX with prolonged ischemic storage. HTX was performed in foxhounds. The ischemic time was standardized to 4 h, 8 h, 12 h or 16 h, depending on the experimental group. Left ventricular (LV) and vascular function were measured. Additionally, the myocardial high energy phosphate and iron content and the in-vitro myocyte force were evaluated. Iron chelator supplementation proved superior at a routine preservation time of 4 h, as well as for prolonged times of 8 h and longer. The supplementation groups recovered quickly compared to their controls. The LV function was preserved and coronary blood flow increased. This was also confirmed by in vitro myocyte force and vasorelaxation experiments. Additionally, the biochemical results showed significantly higher adenosine triphosphate content in the supplementation groups. The iron chelator LK614 played an important role in this mechanism by reducing the chelatable iron content. This study shows that an iron-chelator-supplemented Bretschneider solution effectively prevents myocardial/endothelial damage during short- as well as long-term conservation.

[1]  P. Demondion,et al.  A single‐center long‐term experience with marginal donor utilization for heart transplantation , 2020, Clinical transplantation.

[2]  J. Nilsson,et al.  The influence of ischemia and reperfusion time on outcome in heart transplantation , 2020, Clinical transplantation.

[3]  J. Copeland,et al.  The Effect of Cardiac Preservation Solutions on Heart Transplant Survival. , 2019, The Journal of surgical research.

[4]  B. Merkely,et al.  Myofilament Ca2+ sensitivity correlates with left ventricular contractility during the progression of pressure overload-induced left ventricular myocardial hypertrophy in rats. , 2019, Journal of molecular and cellular cardiology.

[5]  M. Kittleson Recent advances in heart transplantation , 2018, F1000Research.

[6]  J. Ali,et al.  Global Cardioplegia Practices: Results from the Global Cardiopulmonary Bypass Survey. , 2018, The journal of extra-corporeal technology.

[7]  P. Schemmer,et al.  Comprehensive Review on Custodiol-N (HTK-N) and its Molecular Side of Action for Organ Preservation. , 2018, Current pharmaceutical biotechnology.

[8]  Shengshou Hu,et al.  Development and Evaluation of Heartbeat: A Machine Perfusion Heart Preservation System , 2017, Artificial organs.

[9]  A. Israni,et al.  OPTN/SRTR 2015 Annual Data Report: Heart , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  L. Lund,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  Shengshou Hu,et al.  Three Preservation Solutions for Cold Storage of Heart Allografts: A Systematic Review and Meta-Analysis. , 2016, Artificial organs.

[12]  S. Prathanee,et al.  Custodial-HTK Solution for Myocardial Protection in CABG Patients. , 2015, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[13]  L. Dembo,et al.  Successful Heart Transplant after Ten Hours Out-of-body Time using the TransMedics Organ Care System. , 2015, Heart, lung & circulation.

[14]  B. Merkely,et al.  Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass , 2015, Journal of Cardiothoracic Surgery.

[15]  P. Bannon,et al.  Custodiol for myocardial protection and preservation: a systematic review. , 2013, Annals of cardiothoracic surgery.

[16]  M. Karck,et al.  Effects of Custodiol-N, a novel organ preservation solution, on ischemia/reperfusion injury. , 2010, The Journal of thoracic and cardiovascular surgery.

[17]  M. Jessen,et al.  Machine perfusion for cardiac allograft preservation , 2008, Current opinion in organ transplantation.

[18]  H. de Groot,et al.  Improvement of the cold storage of blood vessels with a vascular preservation solution. Study in porcine aortic segments. , 2008, Journal of vascular surgery.

[19]  M. Karck,et al.  Endothelial dysfunction after long-term cold storage in HTK organ preservation solutions: effects of iron chelators and N-alpha-acetyl-L-histidine. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  M. Karck,et al.  Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. , 2007, European journal of pharmacology.

[21]  J. Zweier,et al.  The role of oxidants and free radicals in reperfusion injury. , 2006, Cardiovascular research.

[22]  E. Ragazzi,et al.  The effect of age on the enzyme activities of tryptophan metabolism along the kynurenine pathway in rats. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[23]  P. Macdonald,et al.  Enhanced cardioprotection of the rat heart during hypothermic storage with combined Na+ - H+ exchange inhibition and ATP-dependent potassium channel activation. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  P. Jablonski,et al.  HEART PRESERVATION WITH CELSIOR SOLUTION IMPROVED BY THE ADDITION OF NITROGLYCERINE 1 , 2001, Transplantation.

[25]  F. Petrat,et al.  Hypothermia injury/cold‐induced apoptosis—evidence of an increase in chelatable iron causing oxidative injury in spite of low O2−/H2O2 formation , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  T. Demmy,et al.  Organ preservation solutions in heart transplantation--patterns of usage and related survival. , 1997, Transplantation.

[27]  H. Sato,et al.  The role of nitric oxide and NO-donor agents in myocardial protection from surgical ischemic-reperfusion injury. , 1995, International journal of cardiology.

[28]  R. Virmani,et al.  Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. , 1993, Journal of the American College of Cardiology.

[29]  R. Bolli,et al.  Reperfusion-induced injury manifestations, mechanisms, and clinical relevance. , 1991, Trends in cardiovascular medicine.

[30]  M. Gebhard,et al.  Myocardial Protection , 1980, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai.

[31]  P. Spieckermann,et al.  Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. , 1975, The Journal of cardiovascular surgery.

[32]  W. Paulus,et al.  Sarcomeric dysfunction in heart failure. , 2008, Cardiovascular research.

[33]  U. Rauen,et al.  Histidine-induced injury to cultured liver cells, effects of histidine derivatives and of iron chelators , 2006, Cellular and Molecular Life Sciences.

[34]  T. Hewett,et al.  PKC-alpha regulates cardiac contractility and propensity toward heart failure. , 2004, Nature medicine.

[35]  P. Menasché,et al.  Ischemic preconditioning with opening of mitochondrial adenosine triphosphate-sensitive potassium channels or Na/H exchange inhibition: which is the best protective strategy for heart transplants? , 2001, The Journal of thoracic and cardiovascular surgery.

[36]  H. de Groot,et al.  Protection by glycine against hypoxic injury of rat hepatocytes: inhibition of ion fluxes through nonspecific leaks. , 2000, Journal of hepatology.